Hematology

A new recommendation statement cites a lack of current evidence to assess the benefits of iron deficiency screening and supplementation in pregnant individuals.

A randomized clinical trial found significant improvements in key blood parameters for anemia after grape syrup intervention compared with placebo.

Analysis of the Phase 3 explorer7 study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors.

Axatilimab was awarded approval for the treatment of chronic GVHD in adult and pediatric patients who failed ≥2 prior lines of systemic therapy.

Ravulizumab therapy may enable patients with PNH to achieve activity and patient-reported outcomes comparable to the US general population.

Thrombotic risk is more likely influenced by disease status than hormonal contraception exposure in women with SCD.

Interim analysis of STELLAR showed health-related quality of life domains were within a normal range after hematopoietic cell transplant for SCD.

Nipocalimab led to a substantially higher percentage of live births at 32 weeks’ gestation or later without intrauterine transfusions than the historical benchmark.

Ferritin cutoffs of 30 and 45 ng/mL notably increase the rate of iron deficiency diagnoses.

Emergency department utilization patterns in people with sickle cell disease were impacted by the onset of the COVID-19 pandemic in 4 US states.

Delayed anemia treatment with ESAs was not correlated with worse renal events but elevated the risk of cardiovascular events and all-cause mortality.

Anemia is common in high-risk PCI and is independently associated with major adverse cardiovascular events and major bleeding risk.

Our July 2024 hematology month in review examines the latest updates to the hematological pipeline and key study data informing clinical practice.

Patients with hemoglobin SS sickle cell disease type may experience a significantly elevated risk of retinal vascular occlusion.

Patient factors trended towards an association with a higher risk of proliferative sickle cell retinopathy but did not reach statistical significance.

Giroctocogene fitelparvovec achieved primary and key secondary objectives of superiority compared to routine prophylaxis in hemophilia A treatment.

A study found individuals with type 2 diabetes who received less than 7 hours of sleep had 2.6 increased odds of microvascular disease.

The XTEND-Kids phase 3 trial shows efanesoctocog alfa’s safety and efficacy in children with severe hemophilia A, reducing bleeds with once-weekly dosing.

A study from the ASH Research Network reports positive antibody response and tolerability after mRNA vaccination in people with sickle cell disease.

Interim analysis of the Phase 2 study shows an overall response rate of 40% in patients aged 2 years to younger than 18 years with chronic GVHD.

Most patients administered IV iron after acute bacterial infection did not experience negative clinical outcomes.

Online survey data underlines notable discrepancies across various aspects of ID screening and supplementation in clinical practice for patients with HF.

Iron deficiency and anemia rates were typically higher in less economically developed regions and rural areas in China.

Long-term exposure to proton pump inhibitors and oral anticoagulants was linked to an increased risk of IDA presentation.

Patients with chronic kidney disease and TSAT levels of 30–40% experienced significantly fewer cardiovascular events than those with TSAT of 20–30%.